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Summary Escalating health care costs have made it imperative to evaluate the resources required to diagnose
and treat major illnesses in Canadians. For Canadian men, lung cancer is not only the most common
malignancy, but also the major cancer killer. As of 1994. lung cancer is expected to overtake breast cancer as
the leading cause of cancer deaths in women. This paper presents a detailed description of the methodology
used to determine the direct health care costs associated with 'standard' diagnostic and therapeutic approaches
for lung cancer in Canada in 1988. Clinical algorithms were developed for each stage of non-small-cell lung
cancer (NSCLC) and small-cell lung cancer (SCLC). The algorithms were designed to take the form of
decision trees for each clinical stage of lung cancer. The proportion of patients assigned to each branch was
based upon questionnaire responses obtained from thoracic surgeons and radiation oncologists when presented
with clinical scenarios, and information from provincial cancer registries. Direct care costs were derived
primarly from one provincial fee schedule (Ontario). and costing information obtained during the conduct of
several Canadian clinical trials in lung cancer. Direct costs for diagnosis and initial treatment of NSCLC
(excluding relapse and terminal care costs) ranged from SI7 889 for the surgery post-operative radiotherapy
arm of stages I and II to $6 333 for the supportive care arm (stage IV). The cost of determining relapse for
NSCLC was estimated to be S1 528, and terminal care costs, which included palliative radiotherapy and
hospitalisation. were 510 331. Direct costs for diagnosis and initial treatment of SCLC ranged from S18 691
for limited stage disease to S4 739 for the supportive care arm of extensive disease. The cost of diagnosing
relapse for SCLC was estimated to be SI 590, and terminal care costs averaged $9 966. This report provides an
estimate of the Canadian costs of managing lung cancer by stage and treatment modality. Because the actual
costs of all components of care are not available from any combination of sources, these cost estimates must
be viewed as an idealised estimate of the cost of lung cancer management. However, we believe that the lung
cancer costing model that we have developed provides a level of sophistication which gives a reasonable
estimate of the cost per case of treating NSCLC and SCLC.
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Lung cancer is the most common malignancy in Canada. For
Canadian men, it is associated with the highest rates of both
cancer-related incidence and mortality (National Cancer Ins-
titute of Canada, 1992), and it is expected to overtake breast
cancer in 1994 as the leading cause of cancer deaths in
women (National Cancer Institute of Canada, 1994). Because
it is a major health care problem in Canada, it was thought
useful to develop a model of the management of lung cancer,
and to identify the individual cost components associated
with diagnosis, treatment and terminal care. This paper des-
cribes the model and summarises some of the principal costs
of lung cancer management.
As the choice of therapy for lung cancer is determined by
the histological cell type (small-cell or non-small-cell) and the
extent of disease at diagnosis (tumour stage) (Skarin. 1993),
the model includes algorithms for diagnosis and staging acc-
ording to the two main histological cell types: small-cell and
non-small-cell lung cancer. The model also incorporates
treatment algorithms that include surgery, radiation therapy,
chemotherapy or combinations of these modalities appropri-
ate for tumour type and stage (Shields, 1992).
Methods
Diagnostic modules and treatment algorithms
A number of assumptions and simplifications had to be made
in the construction of the model. For example, the only
diagnostic tests included in the model were those considered
essential to the diagnosis of lung cancer. The investigations
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and the frequency of their use were determined by a panel of
lung cancer specialists at the Ottawa Regional Cancer Cen-
tre. In practice, the diagnosis of lung cancer is not always
straightforward, and additional tests may need to be done to
rule out other possible diagnoses. In addition, patients with
lung cancer often have other medical conditions that require
evaluation before a treatment decision can be made. Because
of their variability, these additional tests were not included in
the model. For these two reasons, the model may tend to
underestimate the actual cost of diagnosing lung cancer. On
the other hand, elderly, frail individuals or those who present
with serious co-morbid conditions are not usually submitted
to a full diagnostic and staging work-up.
Treatment approaches were assigned within the model acc-
ording to the treatment recommendations found in the
National Cancer Institute's Patient Data Query (PDQ)
database. These guidelines were modified for Canadian prac-
tice according to the advice of our lung cancer expert panel
and the responses obtained to a questionnaire on practice
patterns which was completed by all academic Canadian
thoracic surgeons (n = 25) and by 48 of 163 radiation
oncologists (29.4%) listed in the Canadian Association of
Radiation Oncologists membership directory. In the ques-
tionnaire, physicians were presented with a series of scenarios
and asked to estimate the proportion of patients with that
stage and presentation that they would treat and by what
modality. Details of radiotherapy dose and fractionation
were specifically requested. It was assumed that all patients in
the Canadian database had equal access to diagnosis and
treatment and were, in fact, treated.
The duration of hospitalisation for diagnostic work-up and
the initiation of therapy for NSCLC (surgery, radiotherapy)
was obtained from the Ontario Cancer Registry, which main-
tains records on all cancer-related admissions in the province
of Ontario. Hospital and outpatient clinic utilisation for
chemotherapy treatment of SCLC and best supportive care
were extracted from the data collected during previous
studies (BR4 and BR-5) of the National Cancer Institute ofCanada (NCIC) (see below) (Evans et al., 1987; Rapp et al.,
1988).
For ease of presentation and analysis, the care of lung
cancer patients was divided into diagnostic modules and
treatment algorithms appropriate for each cell type and
stage. It was assumed that each component of the treatment
algorithms was self-contained and could be added to other
components as the patient proceeded through the course of
his/her illness.
Cost assessment
All costs were determined in constant 1988 Canadian dollars.
As the fee codes and amounts paid for surgical, laboratory
and other procedures, as well as physician assessments, were
different for each province in Canada, it was decided to use
the fees paid in Ontario under its Health Insurance Plan
(OHIP) as the standard. To determine hospitalisation costs
for the surgical management of lung cancer, data from the
Ontario Cancer Registry were combined with an estimate of
the per diem cost of hospitalisation, which was obtained
from Statistics Canada's 'Annual Return of Hos-
pitals-Hospital Indicators'. The average per diem rate for
tertiary care facilities, where most thoracic surgery is per-
formed, was determined to be $545.19 for 1988-89 (Statistics
Canada, Catalogue 83-233).
Hospitalisation costs for the non-surgical care of lung
cancer cases were extracted from the BR4 and BR-5 trials
conducted by NCIC; BR4 assessed the costs of treating
patients with extensive SCLC (Goodwin et al., 1988), and
BR-5 evaluated the costs of chemotherapy and supportive
care in patients with advanced NSCLC Jaakkimainen et al,
1990). As these studies were reported in 1984 Canadian
dollars, the costs were adjusted according to the increase in
the Canadian Consumer Price Index (CPI) between 1984 and
1988, which, for all items, was 17.5%.
In both studies, the 'hotel-approximation method' was
used, which assumes that certain costs, called hotel costs,
such as heating, lighting, security and housekeeping, are
evenly distributed over all inpatient days, regardless of the
reason for admission. The total cost of these items att-
ributable to inpatient facilities over a given period of time
was averaged over all inpatient days to generate a per diem
hotel cost. The medical care costs included the costs of
nursing care and ward supplies for a typical ward treating
non-surgical lung cancer patients, as well as pharmacy (exc-
luding chemotherapy costs), laboratory and diagnostic
radiology costs. The per diem hotel costs and the medical
care costs of hospitalisation were determined at the Princess
Margaret Hospital, Toronto, and the A. Maxwell Evans
Cancer Clinic at the Cancer Control Agency of British Col-
umbia, Vancouver. Medical care costs were added to hotel
costs to arrive at an average cost of $361.02 per day for the
non-surgical inpatient care of lung cancer patients in 1988
(Goodwin et al., 1988; Jaakkimainen et al., 1990).
The cost ofclinic visits for chemotherapy and radiotherapy
assessment was also determined using the hotel approxima-
tion method. The fixed costs that could be attributed to the
outpatient department were calculated and averaged over all
outpatient visits to the hospital to determine the 'hotel' cost
of each visit. Medical care costs varied according to the
purpose of the visit (medical assessment, chemotherapy
administration, follow-up, etc.) and included such items as
nursing care, physician services, pharmacy (excluding chemo-
therapy administration), laboratory and radiology use, equip-
ment and supplies. Data on the frequency ofclinic visits were
obtained directly from the two clinical trials mentioned
above. Costs of routine haematology, liver function tests and
a chest radiograph were included in each visit.
The costs of chemotherapy administration included the
cost of the chemotherapy drugs, the cost of drug preparation
by pharmacy, the laboratory investigations necessary to
monitor patients during chemotherapy, as well as the fees for
physicians' services.
Finally, the cost of one fraction of radiation was assumed
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to be $145 (1988 Canadian dollars), based on a study by
Wodinsky and Jenkin which was conducted at one of
Ontario's radiation therapy treatment facilities (Wodinsky et
al., 1987). This cost per fraction of radiation therapy
included the salaries and benefits of all staff involved in the
radiation oncology treatment programme (physicians, radia-
tion technologists, physicists, dosimetrists, electronics and
nursing staff), as well as the depreciation of radiotherapy
equipment, the capital cost of the construction of the
radiotherapy treatment facilities and administrative costs.
Reskts
Diagnostic module
The diagnostic module includes those tests, procedures and
assessment fees associated with attending a family physician
because of lung cancer symptoms. On completion of this
initial diagnostic work-up, it is assumed that the patient is
referred to a consultant, who arranges further diagnostic and
staging procedures, including those essential to assess
operability, followed by therapy appropriate for stage. In
practice, not every investigation is performed on every
patient, while at the same time it is also recognised that
certain common tests are often repeated on multiple
occasions, particularly in academic health care facilities. The
extent of this 'excessive' testing is impossible to estimate and
therefore was not included in the model.
It is assumed that all patients have a bronchoscopy with
biopsy as part of the standard work-up. For patients with
metastatic disease, this would not necessarily be done and
may represnt overcounting. However, bronchoscopy may be
performed more than once during the diagnostic work-up
phase of some patients, when more than one specialist is
involved. The continuing involvement of the family physician
in the care of the patient following the diagnosis of cancer is
not costed because of its variability.
The costs associated with the procedures, tests and fees
included in the diagnostic module are shown in Table I. The
most commonly used preoperative investigations are assumed
to be a surgical consultation, ECG, pulmonary function
studies and arterial blood gases. It is assumed that all
patients undergo these investigations to determine oper-
ability. It is also asumed that all surgical candidates undergo
bronchoscopy and cervical mediastinoscopy. The proportion
of patients having preoperative CT scans of the chest is
unknown, and practice varies according to the availability of
CT scanners, the preference of the thoracic surgeon or res-
pirologist and the size and location of the primary tumour.
Certainly, with the increasing availability ofCT scanners, the
proportion of patients undergoing this procedure pre-
operatively is increasing. We, therefore, undertook sensitivity
analyses around the percentage of patients having CT scans
ranging from 50 to 100%.
Therapeutic approachesfor non-small-cell lung cancer
Stage I and II The treatment algorithm for the management
of patients with stage I or II NSCLC is shown in Figure 1.
Based on data from the Ontario Cancer Registry, 88% of
surgially managed patients are treated by lobectomy or
other lung-preserving surgical procedure (segmental resection
or wedge resection). Twelve percent of stage I and H patients
require a pneumonectomy. The cost of surgery includes the
surgical procedure, assistant and anaesthetist fees, pathology
consultation and pathology laboratory technical fees.
The Ontario Cancer Registry provided data on the average
duration of hospitalisation for newly diagnosed lung cancer
patients who underwent surgical resection in 1984. It was
surprising to note that this averaged 20 days in 1984. This
period of hospitalisation was inclusive of the post-operative
recovery period, as well as any in-hospital consultations,
diagnostic tests or staging procedures. Twenty days of hosp-
italisation was used in the model, although data for 1988 and
1990 show a small decline (2 days) in the average length of
stay for initial hospitalisation. Information obtained fromCanaia o caoewco
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our survey of thoracic surgeons imdicated that the usual
post-operative recovery period is 6-8 days depending on the
type of operative procedure. Presumably, the difference
(12-14 days) can be attributed to the diagnostic and staging
work-up or waiting on tests, consults or procedures to be
booked.
In order to estimate the proportion of patients who would
be partially or completely resected, and those who would be
referred for radiotherapy, a questionnaire survey was sent to
25 thoracic surgeons in Canada. All 25 questionnaires were
completed and returned and the average of their responses
was used to estimate the proportion of patients treated at
Table I Component costs of diagnostic module and surgical radiotherapy management of stage I and II NCSLC
Description and costs
Diagnostic
module
Pre-op work-up
Surgical procedure
Radiotherapy
Hospitalisation costs
Follow-up costs in first
year'
Family physician consultation (48.30); haematology (Hb, WBC, differential, platelets); alkaline
phosphatase, SGOT, electrolytes, creatinine, glucose, urinalysis (34.79); sputum cytology
(15.71 x 2 = 31.42); chest radiograph (30.95); follow-up visit (26.40)
Specialist consultant fee (102.45); chest radiograph (30.95 x 2 = 61.90); haematology, alkaline
phosphatase, SGOT, electrolytes, creatinine, urinalysis, glucose (34.79 x 2 = 69.58);
pulmonary function tests (30.20 + 31.50 = 61.70); sputum cytology (15.71 x 2 = 31.42)
Bronchoscopy (102.10); laboratory charges (13.72); interpretation of biopsy (44.95); cytology
of bronchial washings (6.86 + 15.90 = 22.76)
Surgical consultation (52.80); ECG (15.35): arterial blood gases (19.40);
CT scan (thorax) (60.20 x 50/ = 30 10)b
Mediastinoscopy with bronchoscopy (432.51)
Lobectomy to 85% (1 333.13)
Pneumonectomy to 12% (1 413.41) (weighted average = 1 341.56)
Limited resection to 3% (1 292.99)
Radiation consultation (102.45)
Preradiotherapy haematology (31.36)
Weekly haematology (3.92/week x 5 = 19.60)
Radiation therapy (145/treatment x 25 treatments = 3 625)
Hospital costs for diagnosis, surgery and post-operative recovery (545.19 per day x 20
days = 10 903.80)
General assessment (52.40); general reassessment (37.70 x 2 = 75.40); partial assessment
(22.40); chest radiograph (30.95 x 4= 123.80); CBC (3.92 x 4 = 15.68); SMA-6
(17.64 x 4 = 70.56); alkaline phosphatase (4.90 x 4 = 19.60) clinic costs for 1 year (nursing
support, overhead) (53.11 per visit x 17.5% (CPI) = 62.41 x four visits = 249.64)
Total = 629.48
Total
The costing model assumes that the diagnostic module includes the initial medical contact, diagnostic work-up tests and a bronchoscopy with
biopsy. 'Assume annual follow-up costs after first year = S630. bCl scan (thorax) added to 50% of patients only.
Figwe 1 Treatment schema for stage I and II non-small-cell lung cancer. 'Ninety per cent of stage I and 85% of stage II receive
surgical resection. bNinety per cent of stage I and 85% of stage II receive complete resection.
Prcocedure
1988
Ontario
costs (s)
172
327
184
551
1 342
3 779
10 904
630
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each arborisation of the treatment algorithm. Similarly, a
questionnaire survey was sent to the 163 radiation onco-
logists in Canada who are listed in the Canadian Association
of Radiation Oncologists (CARO) membership directory.
Forty-eight responses (29.4%) were obtained and the average
of their responses was used to estimate the proportion of
patients with a particular stage of lung cancer who would
receive radiotherapy, as well as the dose and number of
radiation treatments (fractions).
Patients who undergo a complete surgical resection
(estimated by surgeons at 90% of stage I and 85% of stage
II) are generally followed up without additional treatment.
Twenty percent are assigned post-operative radical radio-
therapy (54 Gy in 25 fractions) in the model, based on the
questionnaire responses. Patients who have an incomplete
surgical resection (estimated as 10% of stage I and 15% of
stage II) are assigned post-operative radiotherapy in the
model. Again, based on the questionnaire responses. these
patients are assigned radical radiotherapy (54 Gy in 25 frac-
tions). It is assumed that 10% of stage I and 15% of stage II
patients are either medically unsuitable for surgical therapy
or refuse surgical resection and that they would be treated by
radical radiotherapy (54 Gy in 25 fractions).
Based on the advice of several academic thoracic surgeons.
we assumed that follow-up in the first year would occur at 3
month intervals and include a physical examination, a chest
radiograph and blood work (complete blood count, SMA-6
and alkaline phosphatase).
As an example of the detailed cost information included in
each diagnostic and treatment algorithm, the cost com-
ponents for one arm of stages I and II NSCLC are presented
in Table I. Detailed cost breakdowns for the remaining treat-
ment algorithms are not included in this document but are
available upon request.
Stage III and IV The diagnostic and treatment algorithm
for the management of patients with stage III or stage IV
NSCLC is shown in Figure 2. Patients with stage Illa and
stage IlIb NSCLC are assumed not to be candidates for
surgical resection, even though patients with single-station
mediastinal nodal involvement (N2) commonly undergo sur-
gical resection, as do those with T3, NO or Nl lesions. Such
cases make up only a small percentage (6%) of all surgically
resected lung cancer (Holmes, 1989). It is also assumed that
only stage Illa patients require mediastinoscopy for staging.
Responses from the questionnaire survey of radiation onco-
logists indicated that they would- treat 85% of the patients
with stage Illa disease with radiotherapy to a moderately
high dose (45 Gy in 20 fractions). A cervical mediastinoscopy
is not included in the model for stage ITlb NSCLC. The dose
of radiation for stage IlIb patients, 80% of whom would be
offered treatment, is less (35 Gy in ten fractions), reflecting
the general tendency to treat these patients less aggressively.
Those patients not radiated receive no active treatment in the
model. The frequency of follow-up assessments and the tests
performed for stage Illa patients after receiving radiotherapy
are assumed to be similar to those assigned to the
radiotherapy arms of stages I and II. The number of follow-
up visits for all other stage III patients is fewer because of
the short (9 months) median survival of these patients.
For patients with stage IV disease, the model assumes that
standard treatment is best supportive care, consisting of
analgesics and antibiotics. These individuals would undergo
10 days of diagnostic assessment, including a bone scan and
a liver ultrasound to stage their disease. It is assumed that
they would incur terminal care costs, consisting of palliative
radiotherapy and hospitalisation, as described below.
Determination of relapse and management of terminal care
(!VSCLC) Patients with localised NSCLC who relapse after
surgery and/or radiotherapy were assigned 2 days of hos-
pitalisation for diagnostic work-up, as Canadian physicians
frequently use this approach to expedite the diagnosis of
relapse. Most of the work-up is done through ambulatory
clinic visits. Investigations apart from blood work included a
bone scan. CT scan and an abdominal ultrasound scan to
identify sites of relapse. It is assumed that those who relapse
and those who are diagnosed with lung cancer in the final
stage (stage IV) would receive terminal care, which would
include palliative radiotherapy, 23.6 days of hospitalisation
and clinic visits, similar to the supportive care patients
managed on BR-5. Palliative radiotherapy is used to relieve
either local symptoms, such as airway obstruction or
haemoptysis. or symptoms of distant metastatic disease, such
as painful bone metastases or neurological deficits from brain
metastases. The average number of treatment fractions
necessary to palliate patients was extracted from the BR-5
study of best supportive care in advanced NSCLC, as was
the average length of terminal care hospitalisation, the total
number of follow-up clinic visits and the amount of nursing
support (Jaakkimainen et al., 1990).
Therapeutic approachesfor small-cell lung cancer
The diagnostic and treatment algorithm for the management
of patients with limited or extensive SCLC is shown in
Figure 2 Treatment schema for stage III and IV non-small-cell lung cancer. aEighty-five per cent of stage IIIA and 80% of stage
IIIB receive radiotherapy. aEight-five per cent of stage IIIA and 80% of stage IIIB receive radiotherapy.
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Figure 3. In the model, patients with SCLC are assigned the
same initial diagnostic tests and assessments as NSCLC, but,
in addition, it is assumed that they receive standard staging
tests, including a bone scan, CT brain scan, abdominal scan
by CT or ultrasound and a bone marrow aspirate and
biopsy.
Lmited disease For patients with limited stage SCLC, stan-
dard treatment is assumed to consist of six courses of
systemic chemotherapy, locoregional radiotherapy and pro-
phylactic cranial irradiation. The standard combination
chemotherapy costed in the model was the three-drug
regimen cyclophosphamide, doxorubicin (Adriamycin) and
vincristine (CAV), alterating with the two-rug combination
ofetoposide and cisplatin. The drug doses and schedule were
the same as those used by the NCIC in its randomised study
(BR4), which demonstrated the superiority of this alter-
nating chemotherapy approach (Evans et al., 1987). It is
assumed that patients with limited disease receive loco-
regional (chest) radiation (40 Gy in 20 fractions), as they did
in another NCIC treatment protocol (BR-3) (Feld et al.,
1987). Furthermore, the model estimates that 70% of
patients receive prophylacc canial irradiation (20 Gy in ten
fractions), based on the fact that virtually all complete res-
ponders and most partial responders receive this treatment in
Canada
The frequency and cost of folow-up visits were extracted
from the BR4 data. After the first year, follow-up consists of
six visits per annum, each of which includes a physical
examination, standard blood work, a chest radiograph and
clinic visit costs.
Extensive disease The chemotherapy treatment costed for
extensive small-cell lung cancer was the same as for imited
The amount ofradiotherapy used in the treatment of
extensive disease was extrcted from the NCIC BR4 study
results. It is estimated that only 30% of extensive stage
patients receive prophylactic canial irradiation. Finally, it is
assumed that 5% of patients with extensive small-cell lung
cancer are either too frail or have medical conditions that
preclude treatment with standard chemotherapy. Tese
patients are assigned 6 days of hospitalisation plus follow-up
costs, which include outpatient assesments, blood work,
chest radiographs and clinic visit costs. It is assumed that
they then receive terminal care, as described below.
Determination of relapse and management of terminl care
(SCLC) Estimates of the cost of diagnosing relapse for
limited disease include blood work, a chest radiograph, a
bone scan, an abdominal ultrasound, 2 days of hospitalisa-
tion and three clinic visits. A CT brain scan is assigned to
half the SCLC patients because of the high frequency of
relapse in the central nervous system (Feld et al., 1984).
Relapsing limited disease patients are not assigned any
further chemotherapy, but are asumed to incur terminal care
costs, consisting of seven fractions of palliative radiotherapy
based on the observed practice during the BR4 trial (Evans
et al., 1987), as well as the cost of 26 days of hospitalisation,
which was the average of the two arms of BR4. Patients
with extensive disase (those who relapse after primary treat-
ment, as well as those who are asumed not to be candidates
for any additional therapy) are assgned only the cost of 26
days of hospitalisation for terminal care.
Swmmy ofcosts by stage and cell type
NSCLC The estimated cost of diagnosis and treatment for
each stage and therapeutic approach of NSCLC is shown in
Table H. It can be seen that the initial cost of diagnosis and
surgical treatment for stage I and II (excluding relapse costs)
was $14 110. The cost ofcombined modality therapy (surgery
plus radiotherapy) for patients with stage I and H was
$17 889. For those patients who were not surgical candidates,
but who were treated with radical radiotherapy, the initial
cost of diagnosis and treatment was estimated to be $12 474.
The irradiation of patients with stage ma and stage IIIb
disease was somewhat less costly, at $11 714 and $9 347
respectively. It was estimated that stage IV patients would
incur an initial cost of $6 333 for their diagnosis. However,
significant costs are incurred when NSCLC patients relapse
and resources are used to diagnose relapse ($1 528) and to
provide terminal care ($10331).
SCLC Table II summarises the costs of diagnosis and
treatment of patients with SCLC by stage and therapeutic
modality. Combined modality therapy for limited disease
F1ge 3 Treatment schema for small-cell lung cancer. Nity-five per cent of extensive disease receive combined chemotherapy
and radiotherapy. bSeventy per cent of limited disca and 30% of treated extensive disease receive prophylactic cnial irradiation.
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Table n Costs of diagnosis and treatment (NSCLC)
Tumour stage Diagnostic Pre-operative Hospitalisation Follow-up
and treatment tests staging tests Surgery Radiotherapy and clinic first vear Total
Stage I + II
Surgery alone 683 551 1342 - 10904 630 14110
Surgery + post-operative
radiotherapy 683 551 1342 3779 10904 630 17889
Radiotherapy only 683 870 - 3748 6543 630 12474
Stage Illa
Radiotherapy 683 835 - 3023 6543 630 11714
No radiotherapy 683 714 - 103' 6543 330 8373
Stage IlIb
Radiotherapy 683 230 - 1561 6543 330 9347
No radiotherapy 683 - - 103a 5452 330 6568
Stage IV
Supportive care 683 198 - - 5452 - 6333
"Additional radiation consultation to determine that radiotherapy will not be administered. Follow-up costs after the first year are assumed
to be similar to those in the first year. Relapse costs (diagnostic tests and hospitalisation) are assigned to all stages except non-radiotherapy
arms of stages Illa and Illb and stage IV and are estimated to be S1528. Terminal care costs of $10331 (palliative radiotherapy and
hospitalisation) are assigned to patients in the year of death.
Table m Costs of diagnosis and treatment (SCLC)
Diagnostic Staging Radio- Chemo- Hospitalisation
Tumour stage and treatment tests tests therapy therapy and clinic Follow-up Total
Limited disease
Chemotherapy + Radiotherapy 683 405 4 065 5 428 8 110 a 18 691
Extensive Disease
Chemotherapy + Radiotherapy 683 405 1 592 3 618 7 027 a 13 335
Palliative care 683 405 - - 3 272 379 4,739
'Follow-upcosts in first yearareincluded incliniccosts. Assumeannualfollow-upcostsafterthefirstyearare S944. Assume
the chemotherapy/radiotherapy arms of limited and extensive disease can relapse. Relapse costs (diagnostic tests and
hospitalisation) aredetermined tobeS 590. Assume terminalcarecostsareassigned topatientsin theyearofdeath. Terminal
care costs for limited disease (palliative radiotherapy and hospitalisation) are S10 544. For extensive disease (hospitalisation
only) they are S9 387.
incurred the highest cost, at 518 691. The combined use of
chemotherapy and radiotherapy does improve survival and
offers a small but definite chance of long-term survival. The
cost of chemotherapy and radiotherapy to palliate a patient
with extensive disease was approximately $13 325. The initial
diagnostic work-up for patients felt to be too frail for
chemotherapy was estimated to cost $4739. The cost to
determine relapse was estimated to be $1 590. Limited disease
SCLC patients who relapsed incurred the additional costs of
$10 544 for palliative radiotherapy and terminal care. Exten-
sive disease patients were assigned only the cost of 26 days of
hospitalisation ($9 387).
The costing model that we have developed assumes that all
patients with lung cancer are treated according to practice
guidelines appropriate to cell type and stage of the disease. In
reality, this is not the case. Data on the demographics of the
Canadian lung cancer population demonstrate that this is a
disease of the elderly (Statistics Canada, 1992). Seventy-five
percent of the patients diagnosed in Canada in 1988 were
older than 60 years of age. Previous studies have shown that
elderly patients with cancer are less likely to receive the same
kind of care as younger patients (Samet et al., 1986; Chu et
al., 1987; Sillman et al., 1989), particularly if they have
NSCLC (Guadagnoli et al., 1990). As lung cancer is a lifes-
tyle disease, often associated with other serious medical con-
ditions and a poor performance status, many clinicians do
not recommend treatment unless there is potential for
curative surgery. In addition, numerous areas of controversy
surround the treatment of locally advanced, inoperable lung
cancer (Durrant et al., 1971; Payne, 1988).
The proportion of patients assigned treatment in the model
was based on the questionnaire responses of thoracic and
radiation oncologists. It is not known how closely the quest-
ionnaire responses conform to actual practice or what pro-
portion of all patients with a particular stage of disease
actually receive the standard therapy. It is certainly true that
there is considerable variation in the radiotherapeutic app-
roach to locally advanced NSCLC in Canada. Duncan et al.
(1993) observed a bimodal distribution of radiation dose
fractionation schedules in response to a questionnaire on
Canadian radiation oncology practice in the palliation of
inoperable lung cancer. Their questionnaire presented clinical
scenarios similar to the questionnaire used to survey onco-
logists for this study. They observed, as did we, a low-dose
group that selected either 20 Gy in five fractions or 30 Gy in
ten fractions and a high-dose group that typically prescribed
60 Gy in 30 fractions. In their 1990 survey, 20% of radiation
oncologists when presented with a clinical scenario of a
symptomatic 59-year-old patient with a hilar mass and
positive mediastinoscopy chose a radical treatment, (30 frac-
tions over 6 weeks), but 56% recommended palliative treat-
ment. The determinants of the dose fractionation schedule
included the age of the radiation oncologist, the geographic
region of the country, departmental policy, workload and
available resources. Significant differences in treatment app-
roaches have been observed in the treatment of inoperable
lung cancer between Canada, the United States and Great
Britain (Maher et al., 1992). Controversy also surrounds the
use of prophylactic cranial irradiation (PCI). In Canada, PCI
is given routinely to limited disease SCLC patients who
achieve a complete remission. Patients with both limited and
extensive disease may also be offered PCI in an effort to
reduce the chances of debilitating neurological symptoms
from metastases. In the United States, PCI is used less
commonly out of concern for post irradiation neurological
syndromes and possible medico-legal action (Kristjansen,
1989).Canadian lung cancer costs
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In the model. we chose to omit chemotherapy costing from
the management of stage IV disease, despite the fact that
Canadian oncologists conducted the pioneering study that
demonstrated that chemotherapy for stage IV disease does
prolong survival (Rapp et al.. 1988). A related study made
the counterintuitive observation that chemotherapy can be
less costly to the health care system than best supportive care
(Jaakkimainen et al.. 1990). Nonetheless, we made this
decision because a survey of Canadian medical oncologists in
early 1985 showed that only 16% of oncologists would opt
for systemic therapy if they themselves had stage IV lung
cancer (MacKillop et al.. 1987). Using the model. we have
undertaken simulations of various chemotherapeutic app-
roaches to stage IV disease which we will report separately.
It is almost certainly true that patients do not have equal
access to care. Patients living in remote areas, aboriginal
peoples and immigrants unfamiliar with the Canadian health
care system may all have difficulty gaining access to standard
care. Unfortunately. it is not possible in Canada to determine
from any database the proportion of patients who actually
receive treatment for any stage of lung cancer. For these
reasons. estimates of the total first year costs for treatment
may exceed the actual expenditures.
Although the costing for diagnostic tests was based on a
knowledge of the usual tests required to make a diagnosis, in
practice patients often present with symptom complexes that
do not initially suggest a diagnosis of lung cancer. As a
result. other investigations may be undertaken which, in
retrospect. are not necessary for the diagnosis of lung cancer.
In addition. tests are frequently duplicated, as patients move
through the health care system from primary care physician
to consultant, particularly within academic health science
centres. In this respect, the estimates for diagnostic tests are
undoubtedly low relative to the actual expenditures. How-
ever, the total amount expended on diagnostic tests is small
and therefore unlikely, even if doubled, to constitute a very
significant component of the total expenditure on lung
cancer. As evidence of this. we did sensitivity analyses for the
frequency of thoracic CT scanning assuming 50%, 75% and
100% usage. In the Canadian health care system, the opera-
tional costs are already absorbed in hospital operating
budgets and reflected in the per diem rate. The only inc-
remental cost is the professional interpretation fee. In the
model, we assumed that 50% of patients were scanned. If
75% were scanned the total health care cost would only
increase by S62 519. If 100% of patients had thoracic CT
scans, the cost increase would be $125 039, a 0.5% increase
in total health care cost.
There are several other areas where the model may have
underestimated costs. It was assumed that radiation therapy
was only administered to outpatients. However, some
patients are too frail or debilitated to be treated on an
ambulatory basis. In addition. some come from remote areas
and are kept in cancer lodges or in hospital until their
radiotherapy treatment has been completed. The proportion
of radiotherapy patients hospitalised for primary therapy has
not been determined, but this would be an important piece of
information for future refinement of the model.
Another source of a downward bias in the cost estimates is
the fact that the model generally assumes that diagnostic
procedures and treatment are uncomplicated. In reality. diag-
nostic and therapeutic interventions can be associated with
side-effects which may be serious and result in delayed hos-
pital discharge or require outpatient assessment and,or read-
mission. For example. a surgical resection may be comp-
licated by wound infection. bronchopleural fistula or
empyema. Radiation therapy to the chest may result in
oesophagitis. requiring hospitalisation for hydration and nut-
ritional support. Chemotherapy may induce febrile neut-
ropenia requiring hospitalisation, or nausea and vomiting
requiring intravenous fluid and nutritional support.
The per diem rate for hospitalisation used for this study is
probably another underestimate. We used the per diem rate
for tertiary care hospitals obtained from Statistics Canada's
'Annual Return of Hospitals-Hospital Indicators. which, in
1988-89 was S545.19 (Statistics Canada. 1991). An estimate
of hospital costs derived from raw utilisation data obtained
from Sunnybrook Medical Centre in Toronto for 29 surgical
patients in 1992 was 5776.10 (M Moffat. unpublished
results). Complications of therapy and co-morbidity as well
as unnecessary test ordering may. in part, explain the higher
cost per day of hospitalisation at Sunnybrook Medical Cen-
tre.
The fact that treatment-related complications are not
generally considered in the NSCLC component of the model
will result in an underestimate of the true cost of lung cancer
management. The hospitalisation and clinic costs associated
with chemotherapy for small-cell lung cancer were extracted
directly from the NCIC BR4 clinical trial and do include the
costs of hospitalising patients for therapy-related complica-
tions. These costs are, therefore. more representative of the
true costs of the management of SCLC.
Finally. the costs of procedures and physician assessments
were based on the Ontario fee schedule, and the cost of
hospitalisation for chemotherapy and supportive care was
derived largely from Ontario data. The cost of a fraction of
radiotherapy was also derived from a study done in a cancer
treatment facility in Ontario. The costs for these various
components of health care will vary somewhat from province
to province. Nonetheless. it is unhkely that there are major
differences in these costs between the provincial health care
systems in Canada.
This research was conducted as part of a larger study. to
provide information on various diseases for a comprehensive
microsimulation model called POHEM (for Population
Health Model). which was developed at Statistics Canada
(Wolfson, 1992). POHEM was designed to simulate the
health status of the Canadian population. by integrating data
on risk factors. disease onset and progression. health care
resource utilisation, direct medical care costs and health out-
comes. POHEM currently models lung cancer, breast cancer.
coronary heart disease. arthritis and dementia, and a number
of diseases are under development.
Despite the various limitations outlined above, the lung
cancer model has a level of sophistication which, we believe,
provides a realistic 'baseline' estimate of the cost per case of
treatment by stage and therapeutic modality. The results of
this lung cancer study have been incorporated into the
POHEM framework (Gentleman et al.. 1991). This means
that POHEM now contains a database against which new
therapeutic or preventive interventions can be evaluated. The
development of models such as the lung cancer model, and
their inclusion in the POHEM framework, allows for the
analysis of the interplay of risk factors, disease states and
costs. It provides a valuable tool to reflect the overall health
status of Canadians and to analyse the impact of health
policies on the Canadian population.
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